Comparison of iRECIST versus RECIST V.1.1 in patients treated with an anti-PD-1 or PD-L1 antibody: pooled FDA analysis | Journal for ImmunoTherapy of Cancer
iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics - The Lancet Oncology
i RECIST A guideline for data management and
EPOS™
iRECIST: how to do it | Cancer Imaging | Full Text
Comparison of Radiological Tumor Response Based on iRECIST and RECIST 1.1 in Metastatic Clear-Cell Renal Cell Carcinoma Patient
iRECIST: how to do it | Cancer Imaging | Full Text
PDF) Comparison of iRECIST versus RECIST V.1.1 in patients treated with an anti-PD-1 or PD-L1 antibody: pooled FDA analysis
CDISC Compliant Implementation of iRECIST and LYRIC for Immunomodulatory Therapy Trials
i RECIST A guideline for data management and
Kaplan-Meier curves of OS and PFS based on iRECIST to compare outcomes... | Download Scientific Diagram
Statistical Analysis Plan Title: A Phase 1/2, Multicenter, Single-Arm, Open-Label, Dose-Escalation Study of Birinapant in Combin
iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. - Abstract - Europe PMC
Simplifying the Derivation of Best Overall Response per RECIST 1.1 and iRECIST in Solid Tumor Clinical Studies
Comparison of Radiological Tumor Response Based on iRECIST and RECIST 1.1 in Metastatic Clear-Cell Renal Cell Carcinoma Patient
Novel oncologic therapy response criteria (iRECIST and more) - Mint Medical GmbH
iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. - Abstract - Europe PMC
Rationale Grows for the Immune-Related Response Criteria
Assessing Immunotherapy Response and Progression
iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics - The Lancet Oncology
iRECIST Overview
CDISC Compliant Implementation of iRECIST and LYRIC for Immunomodulatory Therapy Trials
Response Criteria for Intratumoral Immunotherapy in Solid Tumors: itRECIST | Journal of Clinical Oncology
iRECIST
Response Criteria in Oncologic Imaging: Review of Traditional and New Criteria | RadioGraphics
Comparison of iRECIST versus RECIST V.1.1 in patients treated with an anti-PD-1 or PD-L1 antibody: pooled FDA analysis | Journal for ImmunoTherapy of Cancer
